Exollent Therapeutics

Exollent Therapeutics is a biotechnology company specializing in the development of next-generation exosome-based therapeutics. The company leverages its proprietary Exo-Engine platform to engineer extracellular vesicles for the targeted delivery of diverse therapeutic payloads, including proteins and nucleic acids. Their primary research focus is on oncology and autoimmune diseases, aiming to provide more effective and safer treatment options by improving drug biodistribution and reducing systemic toxicity. Based in Suzhou, China, Exollent is led by industry veterans with extensive experience in vesicle biology and drug development, and is backed by prominent venture capital firms.